Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 256 participants.

Also called NCT03199053

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 256 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03199053
  • EudraCT 2015-005042-66
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Brazil, Canada, Chile, Colombia, Finland, India, Israel, Italy, Malaysia, Mexico, New Zealand, Philippines, Poland, Russia, South Korea, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03199053. Randomized; double masking; primary purpose treatment. Start 2017-10-11 (actual); primary completion 2023-02-01 (actual). Results posted on 2024-04-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Saxagliptin
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct03199053
Content hash
6838533f144dfd6da04b4efd7290f8b3355518a71aace30c5821d114f548c5ad